Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Enanta Pharmaceutica (ENTA)

Enanta Pharmaceutica (ENTA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,756,481
  • Shares Outstanding, K 20,215
  • Annual Sales, $ 122,470 K
  • Annual Income, $ -36,170 K
  • 60-Month Beta 0.64
  • Price/Sales 18.01
  • Price/Cash Flow N/A
  • Price/Book 4.40
Trade ENTA with:

Options Overview Details

View History
  • Implied Volatility 79.92%
  • Historical Volatility 101.96%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 79.92% on 11/26/21
  • IV Low 34.05% on 08/19/21
  • Put/Call Vol Ratio 2.14
  • Today's Volume 22
  • Volume Avg (30-Day) 280
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 342
  • Open Int (30-Day) 136

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -1.29
  • Number of Estimates 3
  • High Estimate -1.21
  • Low Estimate -1.43
  • Prior Year -0.41
  • Growth Rate Est. (year over year) -214.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
73.71 +24.66%
on 11/22/21
102.00 -9.91%
on 11/05/21
+16.61 (+22.06%)
since 10/26/21
3-Month
53.59 +71.47%
on 09/22/21
102.00 -9.91%
on 11/05/21
+37.89 (+70.17%)
since 08/26/21
52-Week
40.32 +127.90%
on 12/29/20
102.00 -9.91%
on 11/05/21
+48.95 (+114.00%)
since 11/25/20

Most Recent Stories

More News
Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Lags Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 6.87% and 33.87%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?...

ENTA : 91.89 (+5.75%)
Enanta Pharmaceuticals: Fiscal Q4 Earnings Snapshot

WATERTOWN, Mass. (AP) _ Enanta Pharmaceuticals Inc. (ENTA) on Monday reported a loss of $24.6 million in its fiscal fourth quarter.

ENTA : 91.89 (+5.75%)
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for...

ENTA : 91.89 (+5.75%)
Is a Surprise Coming for Enanta Pharmaceuticals (ENTA) This Earnings Season?

Enanta Pharmaceuticals (ENTA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

ENTA : 91.89 (+5.75%)
Enanta Pharmaceuticals to Participate in December Investor Conferences

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly,...

ENTA : 91.89 (+5.75%)
Enanta Pharmaceuticals Announces Update to its Hepatitis B Virus (HBV) Program

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced it is discontinuing...

ENTA : 91.89 (+5.75%)
Enanta Pharmaceuticals to Host Conference Call on November 22 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to...

ENTA : 91.89 (+5.75%)
Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for

Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ENTA : 91.89 (+5.75%)
Enanta Pharmaceuticals Reports Positive Final Data from its Phase 1b Studies of EDP-514, a Novel Hepatitis B Virus Core Inhibitor

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced final Phase 1b data...

ENTA : 91.89 (+5.75%)
Zoetis' (ZTS) Earnings and Revenues Surpass Estimates in Q3

Zoetis' (ZTS) earnings and revenues beat estimates in the third quarter of 2021. The company raised its financial guidance for 2021.

ENDP : 5.83 (-3.64%)
ZTS : 219.32 (-1.73%)
ENTA : 91.89 (+5.75%)
FHTX : 13.61 (-4.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown,...

See More

Key Turning Points

3rd Resistance Point 101.37
2nd Resistance Point 97.14
1st Resistance Point 94.51
Last Price 91.89
1st Support Level 87.65
2nd Support Level 83.42
3rd Support Level 80.79

See More

52-Week High 102.00
Last Price 91.89
Fibonacci 61.8% 78.44
Fibonacci 50% 71.16
Fibonacci 38.2% 63.88
52-Week Low 40.32

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar